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Subunit VIII was purified from a preparation of the human heart cytochrome c oxidase and its complete amino acid 
sequence was determined. The sequence proved to be much more related to that of the bovine liver oxidase subunit VIII 
than to that found in bovine heart. Our finding of a ‘liver-type’ subunit VIII in the human heart enzyme suggests that 
either there are no isoforms of human subunit VIII or the human oxidase does not show the type of tissue specificity 
that has been reported for the oxidase in other mammals. 
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1. INTRODUCTION 
Cytochrome c oxidase (EC 1.9.3.1) is located in 
the mitochondrial inner membrane, where it 
catalyses the oxidation of ferrocytochrome c by 
molecular oxygen and contributes to the establish- 
ment of a proton gradient across the membrane. 
The subunit composition depends on the source of 
the enzyme: 3 dissimilar subunits have been iden- 
tified in the oxidase from Paracoccus denitrificans 
111, at least 9 in that from Saccharomyces 
cerevisiae [2], and 13 in mammalian cytochrome c 
oxidase [3]. 
In eukaryotes the three largest subunits, I-III, 
are encoded by the mitochondrial genome [4]. 
Subunits I and II contain the haem a groups and 
copper atoms [5-71, subunit II contains the 
cytochrome c-binding site [8,9], and subunit III is 
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probably involved in the proton-translocating 
function of the enzyme [lO,ll]. The question of 
the function of the 10 smaller, nuclear encoded 
subunits of the mammalian oxidase (IV, Va,b, 
Via-c, VIIa-c, VIII) remains unsettled. 
Kadenbach and co-workers [12] compared the 
enzyme purified from several tissues of the same 
mammalian species and reported tissue-specific 
immunological and electrophoretic differences in 
some of the corresponding subunits. The presence 
of cytochrome c oxidase isoenzymes was later con- 
firmed by extensive N-terminal amino acid se- 
quence data [ 13,141. However, no sound evidence 
has been presented for the existence of isoenzyme 
forms for the human cytochrome c oxidase. 
Recently, many cases of cytochrome c oxidase 
deficiency have been reported [15-l 71. The pa- 
tients usually showed decreased cytochrome c 
oxidase activity in skeletal muscle but normal ac- 
tivity in some other tissues investigated. The ex- 
istence of tissue-specific oxidase isoforms would 
provide an explanation for these observations, 
although other explanations are possible. 
Despite its small size of about 45 residues, 
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subunit VIII seems to be quite variable: the 
homology between bovine heart and liver oxidase 
subunits VIII is weak [13,14]. Therefore, subunit 
VIII was an obvious starting point for our in- 
vestigation of the possible existence of human 
cytochrome c oxidase isoenzyme forms. Surpris- 
ingly, our study revealed that the amino acid se- 
quence of oxidase subunit VIII from human heart 
is closely related to that from bovine liver and 
strikingly different from that of bovine heart. 
2. MATERIALS AND METHODS 
2.1. Isolation procedure for cytochrome c oxidase 
Human hearts were obtained at abduction. Cytochrome c ox- 
idase, from hearts that had become available within 24 h post- 
mortem, was purified essentially according to the method of 
Fowler et al. [18] modified in our laboratory [19] in the follow- 
ing ways: after decreasing the concentrations of deoxycholate 
and KCI by dialysis, pure cytochrome coxidase was precipitated 
between 13 and 20% ammonium sulphate and the final am- 
monium sulphate fractionation in the presence of 3% cholate 
was omitted. For determination of the concentration of 
cytochrome c oxidase an absorption coefficient (reduced minus 
oxidised) of 24.0 mM-“cm-’ at 605 nm was used [20]. 
Bovine heart cytochrome c oxidase was isolated as described 
[18,19]. 
2.2. Fractionation of the subunits of cytochrome c oxidase 
The nuclear encoded subunits were separated from the 
mitochondrially encoded subunits using the method of Power et 
al. [21] with the following modifications: supernatant Sl was 
prepared by incubating the enzyme with 42% acetonitrile for 
1 h on ice, and the pellet was extracted twice more with 42% 
acetonitrile. All supernatants were pooled and designated Sl. 
The final pellet (Pl) was resuspended in 1.25% triethylamine 
(TEA) and 1.25% trifluoroacetic acid (TFA). 1 vol. of the mix- 
ed solvent acetonitrile/l-propanol (1: 1, 0.05% TEA, 0.05% 
TFA) was added to the suspension and the mixture was stirred 
for 3 h on ice. After centrifugation, the supernatant was retain- 
ed and the pellet extracted twice more. The final extraction was 
carried out overnight. All three supernatants were pooled and 
designated supernatant S2. Both supernatants Sl and S2 and 
the final pellet P2 were lyophilized and saved for further 
analysis. 
2.3. Purification of subunit VIII with reversed-phase HPLC 
Subunit VIII was isolated from supernatant Sl. An aliquot of 
supernatant Sl was treated with acetone to remove most of the 
cholate. After centrifugation, the pellet was dissolved in 6 M 
guanidine HCI/O.l% TFA and incubated for 30 min at room 
temperature. Dithiothreitol(l0 mM) was added 15 min prior to 
injection into the HPLC system. HPLC was performed on a 
Brownlee (Santa Clara, CA) column (type RP-300, aquapore 
octyl, 300 A pore size, 7 pm spherical, 220 x 4.6 mm) and a 
guard column (type RP-18 aquapore ODS, 7 pm spherical). The 
HPLC system consisted of two LKB 2150 pumps, a 2152 LC 
controller, a Rheodyne 7125 injector and an LKB Uvicord 2138 
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S detector operating at 280 nm. The solvents used for 
chromatography consisted of 0.05% TFA/O.OS% TEA/S% 
acetonitrile/water (solvent A) and 0.05% TFA/O.OS% TEA in 
acetonitrile (solvent B). 
2.4. Polyacrylamide gel electrophoresis 
SDS-urea gel electrophoresis was performed according to 
Kadenbach et al. [3]. Gels (16 x 18 x 0.15 cm) were prepared 
16 h before use. The samples were incubated for 20 h at room 
temperature in sample buffer containing 0.4% p- 
mercaptoethanol and 8% SDS. We added up to 0.8% p- 
mercaptoethanol 15 min prior to the start of the gel elec- 
trophoresis run. Electrophoresis was carried out first for 1.5 h 
at 16 mA and subsequently for 7-8 h at 26 mA. Gels were 
stained with Coomassie brilliant blue. Silver staining was per- 
formed as in [22]. 
2.5. Determination of the amino acid sequence of subunit VIII 
Automatic sequence analysis was carried out on a 477A 
pulsed-liquid sequencer (Applied Biosystems, USA) with on- 
line analysis of the phenylthiohydantoin amino acids on a 12OA 
PTH analyser (Applied Biosystems). The subunit VIII prepara- 
tion was loaded on a polybrene-containing GFC filter, washed 
by carrying out two Edman cycles. In order to obtain the C- 
terminal peptide, digestion of the remainder of the material 
with Staphylococcus aureus V8 protease (Miles, England) was 
carried out in 0.1 M ammonium acetate (pH 4.0) for 12 h at 
37’C at an enzyme/substrate ratio of 1:40. The peptides were 
separated by reversed-phase HPLC on a Vydac Cd column 214 
TP 54 (4.6 x 250 mm), using the following DuPont equipment: 
an 870 three-piston chromatographic pump, an 8800 gradient 
controller and a UV spectrophotometer set at 220 nm. 
3. RESULTS 
In contrast to the bovine oxidase, sufficiently 
pure human cytochrome c oxidase precipitated be- 
tween 13 and 20% ammonium sulphate saturation. 
Therefore, the final fractionation with ammonium 
sulphate in the presence of cholate was omitted. 
The purity of the isolated enzyme preparation was 
confirmed by its subunit pattern on SDS- 
polyacrylamide gel electrophoresis (fig.1). The 
bands were numbered according to Kadenbach et 
al. [3] using the bovine heart cytochrome c oxidase 
as a reference. The left-hand panel of fig.1 
(Coomassie staining) shows the subunit patterns of 
bovine heart and human heart cytochrome c ox- 
idase. In order to visualise subunit VIII, which 
stains weakly with Coomassie blue, an additional 
silver staining of the gel was performed (right-hand 
panel of fig.1). A comparison of the elec- 
trophoretic mobility of subunit VIII of bovine and 
of human heart cytochrome c oxidase showed that 
the human subunit VIII clearly had a higher 
mobility than its bovine counterpart. This is in 
Volume 240, number 1,2 FEBS LETTERS November 1988 
Fig.1. Subunit composition of human heart cytochrome c 
oxidase and of supernatants Sr and SZ and pellet Pz. Bands 
numbered according to Kadenbach et al. [30]. Bovine heart 
cytochrome c oxidase was used as a reference. Left-hand panel: 
Coomassie staining; right-hand panel: silver staining. The inset 
shows the absorbance spectra of oxidised (-) and dithionite- 
reduced (- - -) human heart cytochrome c oxidase (2.3 ,uM) in 
50 mM Tris-sulphate (pH 8.0). 
agreement with earlier data of Sinjorgo et al. [23]. 
The absorbance spectrum of human heart 
cytochrome c oxidase is shown in the inset to fig. 1. 
The Soret peak of the oxidised enzyme was at 
419 nm, in the reduced form the Soret peak and 
the a-band being at 443 and 604 nm, respectively. 
The absorbance ratios Aus,(red)/&i9,,(ox) = 
1.2 and A443.,(red)/A419,,(red) = 2.2 
demonstrate that the preparation was fully reduci- 
ble. The data are in good agreement with the 
values reported for the small-scale HPLC isolation 
method of human cytochrome c oxidase described 
by Sinjorgo et al. [23]. 
In order to purify subunit VIII of human heart 
cytochrome c oxidase with reversed-phase HPLC, 
we separated the nuclear encoded subunits from 
those encoded mitochondrially by first incubating 
the holoenzyme with acetonitrile at neutral pH, 
followed by extraction with an acetonitrile/l-pro- 
panol mixture at acidic pH (see section 2). The 
three large hydrophobic subunits remained in the 
pellet, eliminating the risk of irreversible binding 
to the stationary phase during reversed-phase 
column chromatography. 
The subunit composition, determined by SDS 
gel electrophoresis, of supernatants Si and SZ and 
pellet P2 is shown in fig. 1. The silver staining of the 
gel (right-hand panel of fig.1) showed that almost 
all of subunit VIII could be extracted via this 
method. Subunit VIII was predominantly present 
in supernatant St, although a small part appeared 
in S2 and in the final pellet Pz. 
Human heart subunit VIII was further purified 
from supernatant Si with reversed-phase HPLC. 
Part of the elution profile of supernatant Si is 
shown in fig.2. Subunit VIII eluted as a small peak 
at approx. 56% solvent B. The purity of the 
polypeptide was tested by SDS gel electrophoresis. 
The inset to fig.2 shows that isolated subunit VIII 
was not contaminated with other polypeptides. 
In table 1 the amino acid sequence of subunit 
VIII from human heart oxidase is presented, 
together with that from bovine heart [24] and the 
major part of the sequence from bovine liver [ 141 
and rat liver subunit VIII [31]. The automatic se- 
quence analysis of approx. 1.5 nm of the human 
polypeptide allowed unambiguous identification 
up to residue His-36. From cycle 37 onwards, a 
substantial carry-over phenomenon occurred. It 
was established that the polypeptide consisted of 
44 residues, but the nature of residues 41 and 44 
was not clear. The exact sequence of the C- 
terminal part of the protein was obtained from se- 
quence analysis of a peptide that eluted at 5.6% 
acetonitrile during HPLC separation of an S. 
aureus protease V8 digest of the protein. The yield 
of the phenylthiohydantoin amino acids in each cy- 
cle was (in pmol): Thr-1, 105.6; Tyr-2, 117.2; 
Arg-3, 21.6; Arg-4, 19.0; Pro-5, 108.8; Glu-6, 
19.1. Subsequent cycles gave no further residues. 
This confirmed and established the sequence of the 
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Fig.2. Part of the HPLC-elution profile of supernatant Sr. The 
inset shows the analysis by gel electrophoresis of the human 
heart subunit VIII purified with reversed-phase HPLC (OX, 
total human heart oxidase). 
129 
Volume 240, number 1,2 FEBS LETTERS November 1988 
Table 1 
Primary structure of human heart cytochrome c oxidase subunit VIII 
1 5 IO 15 
Human heart Ile-His-Ser-Leu-Pro-Pro-Glu-GLy-Lys-Leu-Gly-Ile-Met-Glu-Leu- 
Bovine liver Ile-His-Ser-Lys-Pro-Pro-Arg-Glu-GLn-Leu-Gly-Thr-Met-Glu-Ile- 
Bovine heart Ile-Thr-Ala-Lys-Pro-Ala-Lys-Thr-Pro-Thr-Ser-Pro-Lys-Glu-Gln- 
Rat Liver . . . . . . . . . . . . . . . . . . . . . . . . . . ...*..... -Gly-GLy-Val-Leu-Asp-ILe- 
16 20 25 30 
Human heart ALa-Val-GLy-Leu-Thr-Ser-Cys-Phe-Val-Thr-Phe-Leu-Leu-Pro-Ala- 
Bovine liver ALa-ILe-Gly-Leu-Thr-Ser-Cys-Phe-Leu-Asp-....................... 
Bovine heart ALa-Ile-GLy-Leu-Ser-Val-Thr-Phe-Leu-Ser-Phe-Leu-Leu-Pro-Ala- 
Rat Liver Thr-ILe-GLy-Leu-Thr-Ser-Cys-Phe-Val-Cys-Cys-Leu-Leu-Pro-Ala- 
31 35 40 45 
Human heart Gly-Trp-ILe-Leu-Ser-His-Leu-Glu-Thr-Tyr-Arg-Arg-Pro-Glu 
Bovine liver . . . . . . . . . . . . . . . . . . . . . . . -Met-GLu-Asn-Tyr-Lys-Lys-Arg-Glu 
Bovine heart Gly-Trp-Val-Leu-Tyr-His-Leu-Asp-Asn-Tyr-Lys-Lys-Ser-Ser-Ala-Ala 
Rat liver GLy-Trp-VaL-Leu-Ser-His-Leu-GLu-Ser-Tyr-Lys-Lys-Arg-Glu 
Comparison of the complete amino acid sequence of subunit VIII of human heart cytochrome c oxidase as determined by us, with 
that of subunit VIII of bovine heart [24] and with the partial sequence of bovine liver subunit VIII [14]. The partial sequence given 
for rat liver oxidase subunit VIII was derived from cDNA [31]. Parts of sequences that have not yet been determined are indicated 
by the dotted lines 
of human heart oxidase is two residues shorter 
than that of bovine heart and has the same size as 
subunit VIII of bovine liver. 
4. DISCUSSION 
In this paper we present he complete amino acid 
sequence of human heart cytochrome c oxidase 
subunit VIII that had been purified from the en- 
zyme by solvent extractions and reversed-phase 
HPLC. To our knowledge this is the first amino 
acid sequence of a subunit of human cytochrome 
c oxidase that has been directly determined by pro- 
tein sequencing. From a human liver cDNA bank 
the group of Schon and DiMauro recently obtain- 
ed the nucleotide sequence and the corresponding 
amino acid sequence of the liver form of human 
oxidase subunit VIII (Schon, E.A., personal com- 
munication). The sequence is completely identical 
to that determined by us for the heart protein. This 
is a very unexpected finding because subunit VIII 
is one of the most variable polypeptides in other 
mammals [25-271. This is illustrated by the fact 
that for the first 20 amino-terminal residues, 
subunits VIII from bovine heart and bovine liver 
have only 8 residues in common (table 1). 
Jarausch and Kadenbach [28] proposed that for 
the tissue-dependent subunits Via, VIIa and VIII, 
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tissue specificity overrides species specificity. 
Reasoning along these lines, one would have ex- 
pected that the sequence of the human heart 
subunit VIII should show more homology to that 
of its bovine heart counterpart than to subunit 
VIII from human liver cytochrome c oxidase. 
From the sequence for human heart subunit VIII 
we found that for the first 20 amino-terminal 
residues, there were only 6 residues identical to 
those of bovine heart, but 13 residues of the 
human heart subunit were identical to those of 
bovine liver subunit VIII. Thus, the sequence of 
human heart subunit VIII is much more related to 
that of bovine liver than to its bovine heart 
counterpart. This indicates that in the human 
cytochrome c oxidase a ‘liver form’ of subunit VIII 
is present not only in liver (as deduced from the 
liver cDNA sequence) but also in the heart. A com- 
parison of the human heart sequence with that 
derived from cDNA for rat liver [3 l] also supports 
the notion that a ‘liver type’ subunit VIII is present 
in human heart oxidase. A conspicuous difference 
between the human heart subunit VIII and the 
three other subunits VIII is found near the 
carboxy-terminus, where at positions 41-42 the 
human subunit VIII has two arginine residues, 
while all other subunits VIII have two lysines (see 
table 1). 
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Up to now, our results with subunit VIII of 
human heart cytochrome c oxidase have not sup- 
ported the idea that isoenzyme forms of 
cytochrome c oxidase occur in man, in contrast to 
the situation in other mammals. However, the fact 
that the human heart subunit VIII sequence was 
identical to that deduced from human liver cDNA 
does not prove that there are no isoenzyme forms 
of this subunit present in man. If two isoforms of 
a subunit are strongly dissimilar, a DNA probe 
based on the sequence of one of the isoforms may 
fail to detect the presence of the other. Secondly, 
we have shown the presence of a liver type subunit 
VIII in human heart, but it has not been proved 
that a second, ‘heart type’, subunit VIII is absent 
in our enzyme preparation. It might be relevant 
that a second fraction of subunit VIII was ex- 
tracted with a less polar organic solvent mixture 
(SZ) from the holoenzyme and that part of subunit 
VIII was still present in pellet PZ (see fig.1). This 
issue will be investigated further. 
The occurrence of tissue-specific cytochrome c 
oxidase deficiencies in man has stimulated research 
on the possible existence of tissue-specific isoforms 
of the oxidase. These could either arise from 
separate multiple genes for one or more of the 
subunits or by alternative splicing of a primary 
transcript. Even the presence of two different 
genes coding for the ‘same’ subunit would not 
necessarily lead to the occurrence of isoenzymes, if 
the differences reside only in the presequences. 
This has been found to be the case for the ATP 
synthase proteolipid [29]. Such a difference will 
only be detectable by nucleotide sequencing of the 
gene. Of course, tissue-specific oxidase deficiency 
could also be caused indirectly by a defect in tissue- 
specific proteins or other gene products involved in 
subunit biosynthesis or import, or by a defect in 
the assembly of the oxidase holoenzyme from its 
polypeptides and prosthetic groups. 
Most relevant with respect to cytochrome c ox- 
idase deficiencies is the oxidase that is present in 
skeletal muscle. A disease often described in this 
connection is the form of fatal infantile myopathy 
in which the patient lacks a functional cytochrome 
c oxidase in skeletal muscle while normal levels of 
the enzyme are found in other tissues [13,15-171. 
Investigations of the amino acid sequences of 
several subunits of cytochrome c oxidase from 
human heart and skeletal muscle are in progress in 
our laboratories. This will yield more information 
about the possible existence of human cytochrome 
c oxidase isoenzymes. 
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